Congratulations ! Xantho Bio’s New Drug Nominated for Edison Award, Highlighting Innovation and Strength
The Edison Award is regarded as the "Oscar" in the fields of innovation and business, recognizing the most groundbreaking products and technologies worldwide. Xantho Bio is committed to developing treatments for chronic inflammatory skin diseases using botanical ingredients. Our botanical drug, GM-XANTHO, has recently been nominated for the internationally renowned Edison Award, a significant recognition of our efforts in innovation and excellence.
GM-XANTHO is an innovative botanical medicine derived from mangosteen extract. It demonstrates great potential in treating atopic dermatitis by reducing inflammation and promoting skin repair. Compared to traditional treatments, GM-XANTHO offers a safer alternative, aiming to address the unmet needs of chronic inflammatory skin diseases. Currently, the drug has completed Phase IIa clinical trials and is bringing a new medical option to patients.
We firmly believe that this nomination is an important recognition of Xantho Bio’s focus on botanical drug research and development, and it inspires us to continue advancing in order to provide higher-quality treatment solutions for patients. Stay tuned for more groundbreaking progress from us!
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
